Contract

Research Technician

Antibody Purification

Posted on 6/19/2025

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Biotechnology firm specializing in antibody therapies

Compensation Overview

CA$52.3k - CA$65.4k/yr

+ Bonus

Entry, Junior

Vancouver, BC, Canada

In Person

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • You hold a BSc in Biochemistry, Chemistry, or other Biological Science; additional experience in an academic or industry wet lab environment is an asset
  • You have hands-on experience with protein purification technologies, including IMAC, size exclusion, IEx, and/or affinity chromatography
  • You are excited about organization & digital inventory management
  • You have great interpersonal skills and the interest to work in cross functional scientific teams
  • You are self-motivated and have the initiative and drive to meet goals under tight project timelines
  • You have excellent documentation with the attention to detail and organizational skills
Responsibilities
  • Supporting antibody drug discovery programs by executing midscale antibody purification using instrumentation such as AKTA and Protein Maker preparative liquid chromatography systems
  • Conducting characterization of purified antibodies using analytical techniques such as SDS-PAGE/CE-SDS, ultra high performance liquid chromatography (UHPLC) and endotoxin (LAL) tests
  • Implementing and maintaining antibody inventory system including its operations to support fast pace research environment
  • Utilizing electronic laboratory notebook (ELN) to capture your research results
  • Contributing to optimizing efficiency and speed in antibody production platform

AbCellera specializes in discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies, making the discovery process faster and more efficient. AbCellera collaborates with pharmaceutical companies, biotech firms, and research institutions, providing them with antibody discovery services and licensing its candidates for drug development. What sets AbCellera apart from its competitors is its ability to address challenging targets that traditional methods struggle with. The company's goal is to advance new treatments to market while supporting its partners in their drug development efforts.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Vancouver, Canada

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • AbCellera's collaboration with AbbVie expands its oncology T-cell engager programs.
  • The partnership with Viking and ArrowMark aims to launch new biotech companies.
  • AbCellera's AI-driven discovery platform enhances precision and speed in drug development.

What critics are saying

  • Increased competition from genomic data leaders like Illumina may impact market share.
  • Strategic misalignments with PE partners could affect AbCellera's operational focus.
  • Rapid AI integration in biotech requires AbCellera to enhance its AI capabilities.

What makes AbCellera Biologics unique

  • AbCellera excels in rapid antibody discovery using a proprietary technology platform.
  • The company has strong partnerships with leading pharmaceutical firms like Eli Lilly.
  • AbCellera's focus on challenging targets sets it apart in the biopharmaceutical market.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Sick Leave

Flexible Work Hours

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Business Wire
May 9th, 2025
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera presents positive preclinical data on ABCL575 at the 2025 SID Annual Meeting.

Montreal Gazette
Mar 25th, 2025
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera announces presentation of in vivo data on PSMA x CD3 T-Cell engagers at AACR 2025.

Stock Titan
Jan 13th, 2025
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera (ABCL) has expanded its collaboration with AbbVie (ABBV) to develop novel T-cell engagers (TCE) in oncology, building upon their partnership from December 2022.

North Carolina Biotechnology Center
Sep 30th, 2024
Dualogics Sells Antibody Platform to Canadian Company | North Carolina Biotechnology Center

Durham-based Dualogics has sold its core technology for producing therapeutic antibodies to a Canadian biotechnology company.

Stock Titan
Jul 31st, 2024
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera (Nasdaq: ABCL) has expanded its collaboration with Eli Lilly to develop antibody medicines for immunology, cardiovascular disease, and neuroscience programs.

INACTIVE